AI Article Synopsis
- Anthrax, caused by a specific bacterial pathogen, is a disease that researchers are targeting for vaccine development, focusing on the anthrax protective antigen (PA).
- A modified version of this antigen (rPA83m) has been created to enhance stability by inactivating certain sites that lead to protein breakdown.
- Combining this modified antigen with plant virus particles has proven to be an effective stabilizing method, showing promising results in tests for stability, immune response, and protection in guinea pigs against a dangerous strain, making it a strong candidate for future anthrax vaccines.
Article Abstract
Anthrax is a disease caused by . The most promising approach to the development of anthrax vaccine is use of the anthrax protective antigen (PA). At the same time, recombinant PA is a very unstable protein. Previously, the authors have designed a stable modified recombinant anthrax protective antigen with inactivated proteolytic sites and substituted deamidation sites (rPA83m). As a second approach to recombinant PA stabilisation, plant virus spherical particles (SPs) were used as a stabiliser. The combination of these two approaches was shown to be the most effective. Here, the authors report the results of a detailed study of the stability, immunogenicity and protectiveness of rPA83m + SPs compositions. These compositions were shown to be stable, provided high anti-rPA83m antibody titres in guinea pigs and were able to protect them from a fully virulent 81/1 strain. Given these facts, the formulation of rPA83m + SPs compositions is considered to be a prospective anthrax vaccine candidate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501872 | PMC |
| http://dx.doi.org/10.3389/fmicb.2022.1003969 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!